On April 6, 2017, the U.S. Food and Drug Administration (FDA) allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional. The GHR tests are intended to provide genetic risk information to consumers, but the tests cannot determine a person’s overall risk of developing a . . .